US6536427B2
(en)
|
1990-03-02 |
2003-03-25 |
Glaxo Group Limited |
Inhalation device
|
SK280967B6
(en)
|
1990-03-02 |
2000-10-09 |
Glaxo Group Limited |
Inhalation device
|
GB9004781D0
(en)
*
|
1990-03-02 |
1990-04-25 |
Glaxo Group Ltd |
Device
|
GB9012870D0
(en)
*
|
1990-06-08 |
1990-08-01 |
Glaxo Group Ltd |
Device
|
GB9016789D0
(en)
*
|
1990-07-31 |
1990-09-12 |
Lilly Industries Ltd |
Medicament administering devices
|
US5042472A
(en)
*
|
1990-10-15 |
1991-08-27 |
Merck & Co., Inc. |
Powder inhaler device
|
US5337740A
(en)
*
|
1991-08-01 |
1994-08-16 |
New England Pharmaceuticals, Inc. |
Inhalation devices
|
DE19647947A1
(en)
*
|
1996-11-20 |
1998-05-28 |
Pfeiffer Erich Gmbh & Co Kg |
Discharge device for media
|
SE9900188D0
(en)
*
|
1999-01-22 |
1999-01-22 |
Astra Ab |
Dispensing device
|
US6810872B1
(en)
|
1999-12-10 |
2004-11-02 |
Unisia Jecs Corporation |
Inhalant medicator
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
AR032361A1
(en)
|
2000-08-05 |
2003-11-05 |
Glaxo Group Ltd |
DERIVATIVES OF ANDROSTAN AND SALTS AND SOLVATOS OF THE SAME, ITS USE FOR THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
US7045658B2
(en)
|
2001-03-22 |
2006-05-16 |
Glaxo Group Limited |
Formailide derivatives as beta2-adrenoreceptor agonists
|
WO2002088167A1
(en)
|
2001-04-30 |
2002-11-07 |
Glaxo Group Limited |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
EP1416990A1
(en)
*
|
2001-08-09 |
2004-05-12 |
Glaxo Group Limited |
Inhalation device with a pharmaceutical composition
|
BRPI0212455B8
(en)
|
2001-09-14 |
2021-05-25 |
Glaxo Group Ltd |
compound derived from phenethanolamine for the treatment of respiratory diseases, pharmaceutical formulation, combination, and use thereof
|
US20030235538A1
(en)
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
DE60318193T2
(en)
|
2002-04-25 |
2008-12-04 |
Glaxo Group Ltd., Greenford |
PHENETHANOLAMINDERIVATE
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
US7442839B2
(en)
|
2002-10-28 |
2008-10-28 |
Glaxo Group Limited |
Phenethanolamine derivative for the treatment of respiratory diseases
|
GB0303396D0
(en)
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
PE20050250A1
(en)
|
2003-07-17 |
2005-04-08 |
Glaxo Group Ltd |
ANTAGONISTS OF ACETYLCHOLIN MUSCARINAL RECEPTORS
|
ATE494285T1
(en)
|
2003-10-14 |
2011-01-15 |
Glaxo Group Ltd |
MUSCARINE ACETYLCHOLINE RECEPTOR ANTAGONISTS
|
AP2006003575A0
(en)
|
2003-10-17 |
2006-04-30 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists.
|
TW200524577A
(en)
|
2003-11-04 |
2005-08-01 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
GB0329182D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Chemical compounds
|
EP1725564A4
(en)
|
2004-03-17 |
2007-09-12 |
Glaxo Group Ltd |
M3 muscarinic acetylcholine receptor antagonists
|
BRPI0509382A
(en)
|
2004-04-02 |
2007-09-18 |
Glaxo Group Ltd |
process for the preparation of a compound monohydrochloride salt, crystalline monohydrochloride, process for obtaining crystalline monohydrochloride, method for the prophylaxis or treatment of a clinical condition in a mammal, use of crystalline monohydrochloride, pharmaceutical formulation, and, combination
|
AR050902A1
(en)
|
2004-04-27 |
2006-12-06 |
Glaxo Group Ltd |
QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
|
EP1747219A4
(en)
|
2004-05-13 |
2010-05-26 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists field of the invention
|
EP1848444B1
(en)
|
2005-02-10 |
2016-11-09 |
Glaxo Group Limited |
Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
|
PE20100741A1
(en)
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
|
PE20061351A1
(en)
|
2005-03-25 |
2007-01-14 |
Glaxo Group Ltd |
8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS
|
WO2007022351A2
(en)
|
2005-08-18 |
2007-02-22 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
AR065804A1
(en)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
|
GB2463451A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
|
DK2400950T3
(en)
|
2009-02-26 |
2019-07-29 |
Glaxo Group Ltd |
PHARMACEUTICAL FORMULA comprising 4 - {(1 R) -2 - [(6- {2 - [(2,6-DICHLORBENZYL) OXY] ETHOXY} HEXYL) AMINO] -1-HYDROXYETHYL} -2- (HYDROXYMETHYL) PHENOL
|
TW201111392A
(en)
|
2009-06-16 |
2011-04-01 |
Schering Corp |
Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
EP2611422B1
(en)
|
2010-08-31 |
2018-10-31 |
GlaxoSmithKline Intellectual Property Development Limited |
Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
|
ES2546422T5
(en)
|
2010-08-31 |
2023-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dry powder inhalation medicinal products having moisture control properties and methods of administration thereof
|
WO2012064286A1
(en)
|
2010-11-11 |
2012-05-18 |
Agency For Science, Technology And Research |
Targeting metabolic enzymes in human cancer
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
JP6182594B2
(en)
|
2012-04-27 |
2017-08-16 |
グラクソ グループ リミテッドGlaxo Group Limited |
New compounds
|
EP2925328A1
(en)
|
2012-11-28 |
2015-10-07 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
AR103891A1
(en)
|
2015-03-11 |
2017-06-14 |
Glaxosmithkline Ip Dev Ltd |
PROTEINAS OF UNION TO TSLP, ISOLATED NUCLEIC ACID THAT CODIFIES IT, VECTOR AND HOSPEDADORA CELL THAT UNDERSTAND IT, METHOD TO PRODUCE THE PROTEIN SAID, ITS USE TO MANUFACTURE A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION AND COMPLAINT KIT
|
CN108112251B
(en)
|
2015-06-15 |
2021-03-05 |
葛兰素史克知识产权发展有限公司 |
NRF2 modulators
|
EP3307729B1
(en)
|
2015-06-15 |
2020-09-02 |
GlaxoSmithKline Intellectual Property Development Limited |
Nrf2 regulators
|
KR20180017038A
(en)
|
2015-06-15 |
2018-02-20 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
NRF2 modulator
|
UY36851A
(en)
|
2015-08-16 |
2017-03-31 |
Glaxosmithkline Ip Dev Ltd |
COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS
|
EP3371167A1
(en)
|
2015-10-06 |
2018-09-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Arylcyclohexyl pyrazoles as nrf2 regulators
|
US10364256B2
(en)
|
2015-10-06 |
2019-07-30 |
Glaxosmithkline Intellectual Property Development Limited |
Biaryl pyrazoles as NRF2 regulators
|
JP2019532054A
(en)
|
2016-09-20 |
2019-11-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
TRPV4 antagonist
|
JP7106528B2
(en)
|
2016-09-20 |
2022-07-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド |
TRPV4 antagonist
|
TW201825458A
(en)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產(第二)有限公司 |
TRPV 4 antagonists
|
WO2018104766A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators
|
JP2020500918A
(en)
|
2016-12-12 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
N-arylpyrazoles as NRF2 regulators
|
JP2020500919A
(en)
|
2016-12-12 |
2020-01-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Pyrrole 3-carboxylate as NRF2 regulator
|
JP2020502136A
(en)
|
2016-12-14 |
2020-01-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Bisarylamides as NRF2 regulators
|
EP3555078B1
(en)
|
2016-12-14 |
2024-03-27 |
GlaxoSmithKline Intellectual Property Development Limited |
Bisaryl heterocycles as nrf2 activators
|
JP2020502129A
(en)
|
2016-12-14 |
2020-01-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
3-oxo-1,4-diazepinyl compounds as NRF2 activators
|
BR112019012300A2
(en)
|
2016-12-15 |
2019-11-12 |
Glaxosmithkline Ip Dev Ltd |
nrf2 activators
|
EP3555082B1
(en)
|
2016-12-15 |
2022-01-26 |
GlaxoSmithKline Intellectual Property Development Limited |
Ether linked triazoles as nrf2 regulators
|
AU2018257778B2
(en)
|
2017-04-24 |
2022-02-17 |
Cocrystal Pharma, Inc. |
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
|
JP2021505636A
(en)
|
2017-12-11 |
2021-02-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
NRF2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ failure syndrome
|
WO2019116231A1
(en)
|
2017-12-11 |
2019-06-20 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
GB201720989D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
CN111868063B
(en)
|
2018-01-17 |
2023-08-01 |
葛兰素史克知识产权开发有限公司 |
PI4KIII beta inhibitors
|
EP3796906A1
(en)
|
2018-05-23 |
2021-03-31 |
GlaxoSmithKline Intellectual Property Management Limited |
Indanes as nrf2 activators
|
CA3106556A1
(en)
|
2018-07-27 |
2020-01-30 |
Cocrystal Pharma, Inc. |
Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
|
WO2020055858A1
(en)
|
2018-09-10 |
2020-03-19 |
Cocrystal Pharma, Inc. |
Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
|
BR112021007275A2
(en)
|
2018-10-17 |
2021-07-20 |
Cocrystal Pharma, Inc. |
combinations of influenza virus replication inhibitors
|
CN113164612A
(en)
|
2018-11-13 |
2021-07-23 |
共晶制药公司 |
Formulations of influenza therapeutics
|
WO2020112716A1
(en)
|
2018-11-26 |
2020-06-04 |
Cocrystal Pharma, Inc. |
Inhibitors of influenza virus replication
|
GB201908536D0
(en)
|
2019-06-13 |
2019-07-31 |
Glaxosmithkline Ip Dev Ltd |
Compounds
|
US20230151034A1
(en)
|
2020-03-17 |
2023-05-18 |
Cocrystal Pharma, Inc. |
Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
|
IL297069A
(en)
|
2020-04-10 |
2022-12-01 |
Cocrystal Pharma Inc |
Inhibitors of norovirus and coronavirus replication
|
EP4138884A1
(en)
|
2020-04-20 |
2023-03-01 |
Sorrento Therapeutics, Inc. |
Pulmonary administration of ace2 polypeptides
|
WO2022175425A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Intellectual Property Development Limited |
Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
|
WO2022179967A1
(en)
|
2021-02-23 |
2022-09-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Vadadustat for treating covid-19 in a hospitalized subject
|
IL310394A
(en)
|
2021-08-03 |
2024-03-01 |
Cocrystal Pharma Inc |
Inhibitors for coronaviruses
|